AXL and head and neck cancer: R428, an AXL-specific inhibitor, is not in clinical trials but has been found in preclinical studies to inhibit the growth and migration of erlotinib-resistant head and neck cancer cells [53] (we did not use R428 in the present study owing to an institutional regulatory obligation to the pharmaceutical company).